SCIENTIFIC BACKGROUND

FKBP14, PLOD1

Scientific Background

The autosomal recessively inherited kyphoscoliotic EDS (kEDS) is genetically heterogeneous. Characteristic clinical symptoms include kyphoscoliosis, muscle hypotonia, thin, fragile hyperextensible skin, atrophic scarring, hypermobile joints, and variable eye involvement. Further symptoms are various craniofacial abnormalities, joint contractures, and wrinkled palms.

In the majority of patients, the disease is caused by homozygous or combined heterozygous variants in the PLOD1 gene, which encodes the enzyme lysylhydroxylase 1 (LH) (kEDS-PLOD1). LH is responsible for the hydroxylysine-dependent pyridinoline cross-linking of type I and type III collagen that is mainly found in the skeleton. The absence of the LH enzyme can also be detected by an increased ratio of lysyl-pyridinoline (LP) to hydroxylysyl-pyrodinoline (HP) cross-links in urine.

A small number of patients with nearly identical clinical presentation have an inconspicuous urinary LP/HP ratio and no PLOD1 variants. In 2012, another autosomal recessive EDS type with an inconspicuous LP/HP ratio was described as differential to kEDS-PLOD1 and initially named Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss (EDSKMH). Here, in addition to progressive kyphoscoliosis, muscle hypotonia, joint hypermobility, hyperextensible skin, and myopathy, sensineural hearing loss is particularly characteristic. As a result of clinical overlap with kEDS-PLOD1, EDSKMH is also classified in the kyphoscoliotic EDS (kEDS) group in the current EDS classification, where it is referred to as kEDS-FKBP14. kEDS-FKBP14 is caused by variants in the FKBP14 gene, which encodes FK506-binding protein 22, a member of the peptidyl-prolyl cis-trans isomerases (PPIases).

 

References

Giunta in: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® (May 23, 2019) / Giunta et al. 2018, Genet Med 20:42 / Yeowell and Steinmann in: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® (updated 2018 Oct 18) / Brady et al. 2017, Am J Med Genet C 175:70 / Baumann et al. 2012, Am J Hum Genet 90:201 / Rohrbach et al. 2011, Orphanet J Rare Dis 6:46 / Giunta et al. 2005, Mol Genet Metab 86:269 / Yeowell et al. 2000, Mol Genet Metab 71:212

GENES

FKBP14, PLOD1
How to order

LATEST ARTICLES

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more

In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). ...

Read more

Genetics as we know and understand it today has been shaped, over decades, by the work of many dedicated scientists around the world, and they all de...

Read more